Mary Catchpole, 19, has the same life-threatening genetic condition, activated PI3-Kinase delta syndrome (APDS) ...

Anurag Relan, Pharming Chief Medical Officer, will lead a Q&A session with Dr. Milner and discuss next steps to collaborate with genetic testing laboratories on their VUS reclassification efforts, ...

Pharming Group to host webcast on findings of a new study published in Cell advancing functional classification of variants of uncertain significance (VUS) to improve APDS diagnosis ...

Anurag Relan, Pharming Chief Medical Officer, will lead a Q&A session with Dr. Milner and discuss next steps to collaborate with genetic testing laboratories on their VUS reclassification efforts ...

A Columbia study addresses a key challenge in the diagnosis of rare genetic disorders.

Pharming Group N.V. is a global biopharmaceutical company focused on transforming the lives of patients with rare, debilitating, and life-threatening diseases. The company is involved in the ...

Pharming Group (PHGUF) reports a 42% revenue increase, driven by Ruconest and Joenja sales, while navigating acquisition costs and potential tariff challenges.

Financial highlights On February 14, 2025, the company gained control of Abliva AB by acquiring 88.9% of the issued shares for the amount of US$60.1 million. As of the end of the first quarter of 2025 ...

Examples of forward-looking statements may include statements with respect to timing and progress of Pharming's preclinical studies and clinical trials of its product candidates, Pharming's ...

Pharming Group N.V. (Pharming), a global biopharmaceutical company, announces that the National Institute for Health and Care Excellence (NICE) has issued positive final guidance recommending Joenja ...